Haines Brian B, Ryu Chun Jeih, Chen Jianzhu
Center for Cancer Research, Department of Biology, Massachusetts Institute of Technology, Cambridge, Massachusetts 02139, USA.
Cell Cycle. 2006 May;5(9):913-6. doi: 10.4161/cc.5.9.2732. Epub 2006 May 1.
The recombination activating genes (RAG) play a central role in the generation of a diverse immune repertoire by mediating DNA recombination events at antigen receptor loci in developing B and T lymphocytes. However, inappropriate RAG activity throughout the genome has been implicated in a large variety of human and mouse lymphomas. Mechanisms by which RAG can provoke or perpetuate lymphoma include deregulation of certain genes by translocation to antigen receptor regulatory regions, the formation of chimeric oncogenes, inactivation of tumor suppressor or micro-RNA loci, or activation of oncogenes. Here we present the T cell receptor enhancer (Ebeta) deficient mouse as a tractable in vivo model system to study the role of RAG activity in the context of lymphoma development, and contrast our system with those of others. We posit a general hypothesis that virtually any mutation that impairs early lymphocyte development at stages when RAG is expressed can constitute a pro-carcinogenic event. Our model system provides a means to assess the roles of RAG activity in human lymphoid malignancies.
重组激活基因(RAG)通过介导发育中的B淋巴细胞和T淋巴细胞抗原受体基因座处的DNA重组事件,在产生多样化的免疫库中发挥核心作用。然而,全基因组中不适当的RAG活性与多种人类和小鼠淋巴瘤有关。RAG引发或维持淋巴瘤的机制包括通过易位至抗原受体调节区域使某些基因失调、形成嵌合致癌基因、肿瘤抑制基因或微小RNA基因座失活,或激活致癌基因。在这里,我们展示了T细胞受体增强子(Ebeta)缺陷小鼠,作为一种易于处理的体内模型系统,用于研究RAG活性在淋巴瘤发展背景下的作用,并将我们的系统与其他系统进行对比。我们提出一个普遍假设,即在RAG表达阶段,几乎任何损害早期淋巴细胞发育的突变都可能构成致癌事件。我们的模型系统提供了一种评估RAG活性在人类淋巴恶性肿瘤中作用的方法。